ImClone says mystery bidder will be revealed

ImClone says that it expects a mystery bidder to either reject a takeover move or formally offer $6.1 billion for the biotech company. And ImClone says it will name the bidder one way or the other. In a dig at Bristol-Myers, ImClone says that a competing offer won't be contingent on financing. This is the second time that ImClone has pushed back the deadline on the mystery suitor.

ImClone Chairman Carl Icahn has been heaping scorn on Bristol-Myers Squibb's latest $5.4 billion offer, a $62-per-share bid. But many observers have noted that BMS is still a likely winner in any contest for ImClone, as it already owns 17 percent of ImClone's stock along with U.S. marketing rights to Erbitux.

- check out the Imclone release
- read the report from the Wall Street

Related Articles:
Icahn to BMS: Your $62 hostile bid is 'absurd'
Icahn and Cornelius trade notes, barbs
Icahn's mystery buyer could spark bidding war
ImClone rejects BMS, gets higher bid